Peptides · Evidence-graded entry

Acetyl tetrapeptide-3 and Capixyl claims: what the evidence shows

Name: Acetyl tetrapeptide-3 and Capixyl claims: what the evidence shows
Creator: SoftMaxx AI Editorial
Published: 2026-09-30

Acetyl tetrapeptide-3, evidence-graded: one randomized, triple-blind trial of a blend. Citations checked against PubMed and regulator records.

Written by SoftMaxx AI editorial · Citations checked against PubMed records · Updated 2026-10-01 · Not medically reviewed · How we grade evidence

SoftMaxx AI sells no peptides and takes no vendor money.

The verdict · strongest evidence Human RCT

Human RCT One randomized, triple-blind trial (32 people, 24 weeks) compared a blend of biochanin A, acetyl tetrapeptide-3 and ginseng with 3% minoxidil and found similar gains in terminal hair counts (8.3% vs 8.7%, no significant difference). It had no placebo arm, tested a multi-ingredient blend against 3% rather than 5% minoxidil, and its authors call for larger, longer studies.^[1]

What Acetyl tetrapeptide-3 is

The EU cosmetic-ingredient database (CosIng) describes acetyl tetrapeptide-3 as 'Acetyl Tetrapeptide-3 is product obtained by the acetylation of Tetrapeptide-3', with the function 'skin protecting' (CosIng entry). The one human trial we found tested it inside a blend with biochanin A and ginseng extracts ^[1]. A 2025 review lists Capixyl among the most hyped topical hair actives ^[2]; none of the abstracts we read lists Capixyl's ingredients.

Expert review We found no peer-reviewed test of the mechanisms marketed for it. A 2025 review of the most hyped topical hair actives, Capixyl among them, found the studies mostly small, tested in multi-ingredient formulas, rarely compared with standard therapies, and often with conflicts of interest ^[2]. A 2026 review describes short peptides as a promising approach for hair loss that has limitations ^[3].^[2][3]

Claims vs. evidence

Each popular claim, graded by the strongest study behind it. The words in quotation marks are how the claim is marketed; the text after the grade is what the studies show.

Claim as marketedIncreases hair count in androgenetic alopeciaHuman RCT Blend (biochanin A + acetyl tetrapeptide-3 + ginseng) vs 3% minoxidil, n=32, no placebo; +8.3% vs +8.7% terminal hair counts, difference NS.^[1]
Claim as marketedAs effective as minoxidilHuman RCT The one trial we found compared a blend of biochanin A, acetyl tetrapeptide-3 and ginseng with 3% minoxidil, not 5%, in 32 people, and its authors call for larger, longer studies. A 2025 network meta-analysis confirms the efficacy of minoxidil, finasteride and dutasteride for male pattern hair loss.^[1][4][5]
Claim as marketedBlocks DHTNo supporting study The trial we found reports hair counts and photographic assessment; its abstract does not report a DHT measurement, and we found no human DHT measurement.^[1]
Claim as marketedAnti-inflammatory / follicle anchoringNo supporting study We found no peer-reviewed human or animal study testing this claim. A 2025 review of topical hair actives, Capixyl among them, notes small studies, multi-ingredient formulas and conflicts of interest.^[2]

Common myths, checked

Common beliefCapixyl is proven to work as well as minoxidil.Human RCT One 32-person trial of a blend containing acetyl tetrapeptide-3 found results similar to 3% minoxidil, with no placebo arm, and its authors call for larger, longer studies. A 2025 network meta-analysis of 24 trials confirms the efficacy of topical and oral minoxidil for male pattern hair loss.^[1][5][4]
Common beliefCapixyl contains minoxidil or blocks DHT like finasteride.No supporting study The tested blend contained biochanin A, acetyl tetrapeptide-3 and ginseng extracts, not minoxidil. The trial's abstract does not report a DHT measurement.^[1]

Doses used in studies (not a recommendation)

These are the amounts given to the people, animals or cells in the cited studies, copied as reported. They are a record of what was tested, not dosing instructions, and nothing here says what you should take.

Studied in	Route	Amount reported	How often	How long	n	Source
Humans	topical scalp solution (blend)	1 mL of herbal extract combination (biochanin A, acetyl tetrapeptide-3, ginseng); peptide % not stated in abstract	twice daily	24 weeks	32	^[1] 32 men and women with mild–moderate androgenetic alopecia

Side effects and risks

Human RCT No local adverse reactions reported with the blend (vs one case of scalp eczema with 3% minoxidil)^[1]

Regulatory status (checked 2026-09-30)

United States (FDA)We found no FDA-approved product containing acetyl tetrapeptide-3 in Drugs@FDA (searched 2026-10-01). (FDA: Drugs@FDA search: acetyl-tetrapeptide-3 — no approved product found) FDA does not approve cosmetic products or ingredients (other than color additives) before they go on the market, and a product intended to affect the structure or any function of the body is legally a drug. (FDA: Is It a Cosmetic, a Drug, or Both?)
CanadaWe found no product containing acetyl tetrapeptide-3 in Health Canada’s Drug Product Database (searched 2026-10-01). (Health Canada: Health Canada Drug Product Database search: acetyl-tetrapeptide-3 — no product found)
Sport (WADA)WADA’s Prohibited List does not name acetyl tetrapeptide-3. WADA states that topical cosmetic products may contain prohibited peptides or growth factors and that using cosmetic products containing such substances is prohibited; we found no WADA statement on whether acetyl tetrapeptide-3 is one of them. (WADA: World Anti-Doping Code International Standard Prohibited List 2026; WADA: World Anti-Doping Agency Prohibited List)

Official sources: FDA: Is It a Cosmetic, a Drug, or Both? · WADA: World Anti-Doping Code International Standard Prohibited List 2026 · WADA: World Anti-Doping Agency Prohibited List

Report a side effect

If something went wrong after using any product, tell a clinician and report it. Reports are how regulators find contaminated or mislabeled products.

FDA MedWatch (United States)
Canada Vigilance Program (Canada)

Common questions

Capixyl vs minoxidil which is better?

Human RCT The one trial we found compared a blend of biochanin A, acetyl tetrapeptide-3 and ginseng with 3% minoxidil, not 5%, in 32 people, and its authors call for larger, longer studies. A 2025 network meta-analysis confirms the efficacy of minoxidil, finasteride and dutasteride for male pattern hair loss.^[1][4][5]

Does capixyl block DHT?

No supporting study We found no human study that measured DHT. The one human trial we found, of a blend containing acetyl tetrapeptide-3, reports hair counts and photographic assessment; its abstract does not report a DHT measurement.^[1]

Acetyl tetrapeptide-3 vs minoxidil?

Human RCT One 32-person trial of a blend containing acetyl tetrapeptide-3 found results similar to 3% minoxidil, with no placebo arm, and its authors call for larger, longer studies. A 2025 network meta-analysis of 24 trials confirms the efficacy of topical and oral minoxidil for male pattern hair loss.^[1][5][4]

Is capixyl safe?

Human RCT No local adverse reactions reported with the blend (vs one case of scalp eczema with 3% minoxidil).^[1]

References

Every reference below was matched to its PubMed or DOI record (title checked) before publication. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.

An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial. J Clin Aesthet Dermatol (2020). PubMed 33584955
Topical Alternatives for Hair Loss: Beyond the Conventional. Int J Trichology (2025). PubMed 40654553 DOI
Overview of Short Peptides for Hair Loss. Biomedicines (2026). PubMed 42072405 DOI
Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol (2022). PubMed 35107565 DOI
Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study. J Cosmet Dermatol (2025). PubMed 41051009 DOI

Written by SoftMaxx AI editorial · Citations checked against PubMed records · Updated 2026-10-01 · Not medically reviewed. Editorial standards · Evidence grading and update log.